MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

WIB_icon

Short Telomere Length Increases Non-Relapse Mortality Risk After Allogeneic Transplant for MDS

According to research published in Blood, shorter telomere length was an independent risk factor for non-relapse mortality (NRM) and overall survival (OS) in patients...

FDA Approves Decitabine and Cedazuridine Combination for MDS

The FDA approved an oral combination of decitabine and cedazuridine for adults with myelodysplastic syndromes (MDS), including: those with previously treated and untreated, de...

Study Supports Earlier, More Frequent Use of Hospice in Older Patients With Hematologic Malignancies

Earlier and more frequent hospice use may be associated with a lower probability of inpatient death and a reduction in aggressive care at end...

Cutaneous Toxicities Are Underestimated in Patients With MPNs Receiving Hydroxyurea

A prospective study from Germany has found that, in patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs), treatment with hydroxyurea (hydroxycarbamide) is associated with a substantially...
On location

Evaluating MBG453 Plus Decitabine or Azacitidine in High-Risk MDS and AML

The anti-TIM-3 checkpoint inhibitor MBG453, when added to decitabine or azacitidine, was associated with antileukemic activity and durable response rates in patients with higher-risk...
On location

CC-486 Improves Transfusion Independence in MDS, but Adverse Events Are Common

For patients with lower-risk myelodysplastic syndromes (MDS) and both red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia, CC-486, an oral formulation of the hypomethylating...
WIB_icon

IWG-PM Publishes Proposed Diagnostic Criteria for SF3B1-Mutant MDS

The International Working Group for the Prognosis of MDS (IWG-PM) has published a proposal for new diagnostic criteria for SF3B1-mutant myelodysplastic syndromes (MDS) as...

Luspatercept-aamt Approved for Anemia in Adults With MDS

The FDA has approved luspatercept-aamt for the treatment of anemia that requires 2 or more red blood cell transfusions over 8 weeks in adults...

Putting Mutation Testing in Myeloid Malignancies to the Test

In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...

Chk1 Inhibition Shows Efficacy for Splicing Factor Mutant MDS and Leukemia

A new study found Chk1 inhibition with or without splicing modulators may be an effective targeted treatment approach for splicing factor mutant myelodysplastic syndromes...